Fig. 4. (A) Total ADC pharmacokinetic study in Sprague-Dawley rats after a single intravenous ADC dose of 3 mg kg–1 and (B) associated clearance rates (two-compartmental model analysis) as a function of the hydrophobicity masking entity length (monomer units). (C) Antitumor activity in SCID/BT-474 breast cancer model following a single intravenous ADC dose of 2.5 mg kg–1. No body-weight changes were observed during the study.
